Applied Pharmaceutical Analysis 2025
In-Person Event
October 6 - 8, 2025
Sanofi, Cambridge, MA
Regulated Bioanalysis Workshop - Monday, October 6, 2025
Discovery Bioanalysis and New Technologies Workshop - Tuesday, October 7, 2025
Mechanistic ADME Workshop - Wednesday, October 8, 2025
APA 2025 Program
 |
PLENARY LECTURE Chandra Prakash, PhD Senior Research Fellow @ Agios Pharmaceuticals Human Mass Balance and Metabolite Profiling Studies: Regulatory Guidance, Technical Approaches and Clinical Implications |
|
|
 |
Patrick Breslin Principal Scientist @ Johnson & Johnson Innovative Medicine Recommendations on cross-validation experiment design from bioanalytical and clinical pharmacology perspective - Title TBA |
 |
Wenkui Li, PhD Director Bioanalytics @ Novartis Institutes for BioMedical Research (NIBR) Metabolite bioanalysis on behalf of IQ consortium - Title TBA |
|
Audrey Goddard, PhD Executive Director, Biomarker Sciences & Diagnostics @ Gilead Sciences Title TBA |
 |
Lindsay King, PhD Executive Director, Head Clinical and Translational Biomarkers, Translational Clinical Science @ Pfizer Biomarker validation strategies in drug development - Title TBA |
|
 |
Krisna Duong-Ly, PhD Associate Principal Scientist @ Merck Identification of Critical Reagents for Novel Biotherapeutic Modalities: Considerations and Case Studies |
 |
Rosemary Lawrence-Henderson Principal Scientist @ Pfizer Characterization of Critical Reagents with Different New Modalities |
 |
Amy Li, PhD Principal Scientist @ Genentech Using S/N for ADA assays - Title TBA |
 |
Kiyoto Aramis Tanemura, PhD Research Investigator, Quantitative Systems Pharmacology @ BMS ML Guided Chiral Chromatography Conditions Selection |
 |
Stephanie Pasas Farmer, PhD President and Founder @ BioData Solutions Consulting and Software AI/ML with real world examples - Title TBA |
 |
Jan Elias, PhD Principal Scientist @ Boehringer Ingelheim Title TBA |
 |
Diana Cha, PhD Principal Scientist @ Alnylam Pharmaceuticals LBA approaches and innovations - Title TBA |
 |
John Chen, PhD Senior Vice President @ NovaBioAssays work on LC-MS analysis of the oligonucleotides - Title TBA |
 |
Yunlin Fu, PhD Senior Principal Scientist @ Novartis Bridging HELISA and LC-MS for Quantification of siRNA and Its Metabolite in Preclinical Studies |
 |
Emilee Knowlton, PhD Immunology Sales Specialist @ ProImmune, Inc. immunopeptidomics for immunogenicity - Title TBA |
 |
Xiaobin Zhang, PhD Associate Director @ Takeda Immunogenicity Risk Assessment at the pre-IND Stage: Integrated Immunogenicity Risk Assessment in Protein-based Biotherapeutic Drug Development |
 |
Mark Niosi Principal Scientist @ Pfizer Title TBA |
 |
Dave Wagner, PhD Director, Head of DMPK @ Relay Therapeutics Title TBA |
 |
Martin Dowty, PhD Scientific Director, DMPK/Safety Development Biological Sciences @ AbbVie DMPK Considerations for the Development of Targeted Covalent Inhibitor Drugs: An IQ Consortium Assessment |
 |
Aimee Mattei, PhD Director of Immunoinformatics @ EpiVax In Silico Immunogenicity Risk Assessment: AI-Enhanced Prediction of Clinical Immunogenicity Outcomes with EpiVax's ISPRI Toolkit |
 |
Fabio Broccatelli, PhD Head of DMPK and Computational Chemistry @ Altos Labs Title TBA |
 |
Yipei Zhang, PhD Senior Scientist @ Takeda A Two -cycle Immunoaffinity Enrichment Strategy with Acid Treatment to Enhance Biotherapeutics Assay Sensitivity in Tissues |
|
|
APA 2025 Sessions
Regulated Bioanalysis Workshop
Session I: Regulated BA - Precision Strategies in Regulated BA & Biomarker Validation
Session II: Analytical Innovations in Emerging Modalities & Nucleic Acid-Based Therapies
Session III: Immunogenicity Matters: Advances in ADA Assay Development and Monitoring
Session IV: Beyond Buzzwords: Real-World AI and ML Applications in Bioanalysis
Session V: Rapid Fire Poster Presentations
Discovery Bioanalysis and New Technologies Workshop
Session I: Oligonucleotide Bioanalysis & Therapeutic Nucleic Acids
Session II: Immunogenicity & ADA Assessment
Session III: AI & Machine Learning in Bioanalysis and Drug Discovery
Session IV: Complex Biologics & Bioanalytical Strategies & Biomarker Analysis and Applications in Drug Development
Mechanistic ADME Workshop
Session I: PROTACs and Molecular Glues with respect to ADME challenges and human PK/dose projection; Early dose prediction strategies
Session II: Use of AI & ML for early dose prediction and ADME properties
Session III: Building reliable screening funnels for Targeted Covalent Binders
Session IV: Recent progress on understanding mechanisms of hepatotoxicity
Join our Linkedin Group:
